2022
Variability in Antithrombotic Therapy after Infrainguinal Lower Extremity Bypass
Brahmandam A, Lee M, Bellamkonda K, Provance JB, Sumpio B, Ochoa Chaar CI, Smolderen KG, Mena-Hurtado C, Guzman RJ. Variability in Antithrombotic Therapy after Infrainguinal Lower Extremity Bypass. Annals Of Vascular Surgery 2022, 88: 51-62. PMID: 36245106, DOI: 10.1016/j.avsg.2022.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsFibrinolytic AgentsHumansIschemiaLower ExtremityPeripheral Arterial DiseasePlatelet Aggregation InhibitorsRetrospective StudiesRisk FactorsTreatment OutcomeConceptsInfrainguinal lower extremity bypassLower extremity bypassDual antiplatelet therapySingle antiplatelet therapyAntithrombotic therapyCombination therapyAntiplatelet therapyMedian odds ratioExtremity bypassDistal targetsHierarchical multivariable logistic regressionCenter-level variabilityCommon combination therapyPatient-level factorsPercutaneous coronary interventionPeripheral vascular interventionsMultivariable logistic regressionMultivariable regression modelsAntiplatelet monotherapyBypass targetAntithrombotic regimensPostoperative bleedingTriple therapyCoronary interventionAntithrombotic strategiesAntiplatelet regimens following carotid artery revascularization
Lee M, Ahmed ZV, Huang J, Brice A, Arham A, Castro-Dominguez Y, Aboian E, Nagpal S, Smolderen KG, Mena-Hurtado C. Antiplatelet regimens following carotid artery revascularization. American Heart Journal 2022, 253: 48-52. PMID: 35863439, DOI: 10.1016/j.ahj.2022.07.004.Peer-Reviewed Original ResearchMeSH KeywordsCarotid ArteriesCarotid StenosisEndarterectomy, CarotidHumansPlatelet Aggregation InhibitorsRetrospective StudiesRisk FactorsStentsStrokeTreatment OutcomeConceptsDual antiplatelet therapySingle antiplatelet therapyCarotid artery stentingCarotid endarterectomyAntiplatelet therapyReal-world clinical practiceCarotid artery revascularizationLow adherence ratesArtery revascularizationArtery stentingAdherence ratesClinical practicePatientsTherapyEngland dataHigh percentageRevascularizationAntiplateletEndarterectomyStenting
2021
Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry
Lee M, Ahmed ZV, Huang J, Jelani QU, Aboian E, Peri-Okonny PA, Smolderen KG, Mena-Hurtado C. Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry. American Heart Journal 2021, 244: 31-35. PMID: 34688650, DOI: 10.1016/j.ahj.2021.10.186.Peer-Reviewed Original ResearchMeSH KeywordsDual Anti-Platelet TherapyFibrinolytic AgentsHumansPlatelet Aggregation InhibitorsRegistriesRisk FactorsTreatment OutcomeConceptsPeripheral vascular interventionsDual antiplatelet therapySingle antiplatelet therapyAntiplatelet therapyVascular interventionsOptimal medical therapyNew trial dataAntithrombotic prescriptionMedical therapyPrescription ratesProvider factorsVQI registryTrial dataTherapyHealth systemPatientsTreatment variabilityPractice levelInterventionHigh levelsRegistryPhysiciansLack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation Inhibitors
2020
Physical Activity After Treatment for Symptomatic Peripheral Artery Disease
Peri-Okonny PA, Patel S, Spertus JA, Jackson EA, Malik AO, Provance J, Mena-Hurtado C, Shishehbor MH, Hijjaji V, Gosch KL, Smolderen K. Physical Activity After Treatment for Symptomatic Peripheral Artery Disease. The American Journal Of Cardiology 2020, 138: 107-113. PMID: 33065083, PMCID: PMC7736254, DOI: 10.1016/j.amjcard.2020.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnkle Brachial IndexConservative TreatmentEndovascular ProceduresExerciseExercise TherapyFemaleHealth StatusHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntermittent ClaudicationLeisure ActivitiesLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPatient SatisfactionPeripheral Arterial DiseasePlatelet Aggregation InhibitorsQuality of LifeSedentary BehaviorSmoking CessationSocial InteractionVascular Surgical ProceduresWorkConceptsPhysical activity levelsPhysical activityInvasive treatmentSymptomatic peripheral artery diseasePeripheral artery diseaseMultivariable logistic regressionAssociation of treatmentActivity levelsMultivariable linear regressionHealth status changesHealth status gainsPAD outcomesArtery diseaseVascular clinicInvasive groupNoninvasive treatmentHealth statusLogistic regressionActivity statusLTPAClaudicationTreatmentPatientsStatus changesAssociationAssociation of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial
Rymer JA, Mulder H, Smolderen KG, Hiatt WR, Conte MS, Berger JS, Norgren L, Mahaffey KW, Baumgartner I, Fowkes FG, Katona BG, Rockhold F, Jones WS, Patel MR. Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial. Journal Of The American Heart Association 2020, 9: e016573. PMID: 32924754, PMCID: PMC7792388, DOI: 10.1161/jaha.120.016573.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesDouble-Blind MethodFemaleHealth Status IndicatorsHumansLower ExtremityMaleMiddle AgedOutcome Assessment, Health CarePeripheral Arterial DiseasePlatelet Aggregation InhibitorsQuality of LifeSurveys and QuestionnairesSymptom AssessmentTicagrelorVascular Surgical ProceduresVisual Analog ScaleConceptsMajor adverse cardiovascular eventsMajor adverse limb eventsAdverse cardiovascular eventsAdverse limb eventsLower extremity revascularizationPeripheral artery diseaseCardiovascular eventsHealth status instrumentsLimb eventsEUCLID trialVAS scoresArtery diseaseEQ-5DQuestionnaire scoresSubsequent major adverse cardiovascular eventsLow ankle-brachial indexSymptomatic peripheral artery diseaseLower extremity revascularization proceduresBaseline EQ-5DAnkle-brachial indexHealth status scoresEQ-5D scoresHealth status measurementHealth status changesSubsequent end points
2013
Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry
Smolderen KG, Spertus JA, Tang F, Oetgen W, Borden WB, Ting HH, Chan PS. Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry. Journal Of The American College Of Cardiology 2013, 61: 1069-1075. PMID: 23375933, PMCID: PMC3641586, DOI: 10.1016/j.jacc.2012.11.058.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAmbulatory CareAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDrug UtilizationFemaleHumansHypolipidemic AgentsInsurance, HealthMaleMedicaidMedically UninsuredMedicareMiddle AgedPlatelet Aggregation InhibitorsRegistriesUnited StatesUnited States Department of Veterans AffairsUnited States Indian Health ServiceConceptsCoronary artery diseaseUninsured patientsEvidence-based treatmentsInsurance statusARB therapyAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersEnzyme inhibitors/angiotensin II receptor blockersAngiotensin II receptor blockersNational Cardiovascular Data RegistryPublic insuranceEvidence-based medicationsLipid-lowering therapyII receptor blockersLeft ventricular dysfunctionHealth insuranceTreatment differencesPoisson regression modelsPINNACLE RegistryPhysician adherenceVentricular dysfunctionReceptor blockersArtery diseaseCardiac RegistryCardiac outpatientsData registry